RAPT Therapeutics (RAPT) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
RAPT Therapeutics, Inc. (RAPT) focuses on developing small molecules for immunology through alliances with oncology centers, which increases the likelihood of acquisition. The business relies on trial data, ignoring economic cycles. The absence of commercial products leads to a planned cash burn. This EV/EBITDA price chart, serving as confirmation of the market valuation, recorded the metric at 0.00, confirming the company's current status.
RAPT Therapeutics Inc. - analytical breakdowns and key metrics (RAPT)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity RAPT Therapeutics, Inc.|RAPT - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital RAPT Therapeutics, Inc.|RAPT - Company Cumulative Debt|Debt to Book Capitalization Ratio RAPT Therapeutics, Inc.|RAPT - Company Long-Term Loans and Borrowings|Company Short-Term Debts RAPT Therapeutics|Quick Liquidity rapt.com
- business earnings and investment ratios data:
RAPT - Profit After Tax|Future Profit RAPT Therapeutics, Inc.|RAPT - Market Price to Net Income Ratio|Projected Price to Earnings RAPT Therapeutics|RAPT - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio RAPT Therapeutics, Inc.|RAPT - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) RAPT Therapeutics|RAPT - Earnings per share for the trailing year|Quarterly EPS earnings growth rapt.com|RAPT - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year RAPT Therapeutics, Inc.
Initial company analysis:RAPT (RAPT Therapeutics)
The EV/EBITDA multiple compares the total enterprise value, including net debt, with operating profit before taxes and amortization. This metric allows an investor to assess the real value of assets relative to their ability to generate cash flow. Analyzing the EV/EBITDA multiple of a capital-intensive enterprise helps identify the issuer's stage of maturity. For RAPT Therapeutics, Inc. (RAPT), this is critical when diversifying development in oncology and inflammation therapy.
Key competitors
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation DNTH (Dianthus Corp)|PHVS: EV/EBITDA Multiple|AbCellera (ABCL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tourmaline Bio|Precigen Inc - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio PHAR (Pharming)|Enterprise Value to Operating Income Before Depreciation Ratio NKTR|Upstream Bio Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ZBIO|IMNM: Enterprise Value to EBITDA Ratio|Gossamer Bio Inc - Enterprise Value to Operating Income Before Depreciation Ratio|KALV: EV/EBITDA Multiple|Septerna Pharma - Business Value to Operating Income Before Depreciation|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|Company Value to EBITDA savarapharma.com SVRA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rigel Pharmaceuticals, Inc. (RIGL)|ANAB (AnaptysBio Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATXS (Astria Pharma)|EV/EBITDA Multiple enGene Corp ENGN|JBIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ACRS|KYTX: EV/EBITDA Multiple|Company Value to EBITDA Tiziana Life Sciences Ltd. (TLSA)|Enterprise Value to EBITDA Ratio CABA|EV/EBITDA Multiple Ventyx Biosciences, Inc|Enterprise Value to EBITDA Ratio THTX (Theratechnologies Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio AVTX|EV/EBITDA Multiple ELDN (Eledon Pharmaceuticals, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Agenus, Inc. (AGEN)|Climb Bio, Inc. - EV/EBITDA Multiple|zurabio.com (ZURA) - Enterprise Value to EBITDA Ratio|aTyr Pharma, Inc. (ATYR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADAG - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio IMA|STTK: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple EQ|Total Company Value to Operating Income Before Depreciation Ratio connectbiopharm.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immunic IMUX|ATRA: Enterprise Value to Operating Income Before Depreciation|InflaRx GmbH - EV/EBITDA Multiple|X4 Pharmaceuticals Inc. (XFOR) - Enterprise Value to EBITDA Ratio|ACET (adicetbio.com) - Enterprise Value to EBITDA Ratio|CELU - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INmune Bio, Inc.|BRNS: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KZR|EV/EBITDA Multiple SAB Biotherapeutics Inc. (SABS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akari Therapeutics plc AKTX|ENLV (Enlivex Therapeutics Ltd) - Company Value to Operating Income Before Depreciation Ratio|QTTB: Enterprise Value to EBITDA Ratio|geovax.com - Enterprise Value to Operating Income Before Depreciation Ratio|Edesa Biotech (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio IBIO (iBio Inc)|CARM (Carisma Therapeutics Inc) - EV/EBITDA Multiple|XTLB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLT|EV/EBITDA Multiple hcwbiologics.com (HCWB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptevo Therapeutics Inc. APVO|Business Value to Operating Income Before Depreciation AIM|ADTX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRI Bio Corporation (GRI) - Enterprise Value to EBITDA Ratio|XRTX: EV/EBITDA Multiple|reshapelifesciences.com (HIND) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio REVB|INDP: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SCNI|Total Company Value to Operating Income Before Depreciation Ratio calcimedica.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK - Enterprise Value to EBITDA Ratio|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGM Biosciences, Inc. (IGMS) - Enterprise Value to EBITDA Ratio|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Ocean Biomedical Corp (OCEA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|Enterprise Value to Operating Income Before Depreciation THRD (thirdharmonicbio.com)
